Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02950259
Recruitment Status : Active, not recruiting
First Posted : November 1, 2016
Last Update Posted : May 15, 2018
Brooklyn ImmunoTherapeutics, LLC
Information provided by (Responsible Party):
Providence Health & Services

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : April 26, 2018
  Estimated Study Completion Date : November 2018